Interestingly these hotspots, which we termed SETD2-m6A co-regulated targets, included genes such as LY96 that not only show higher expression in ccRCC and reduced RCC-specific survival, but have also been implicated in M2 macrophage infiltration in RCC to promote chemotherapy resistance [58]. This evidence concerns the gene LY96 and nonpapillary renal cell carcinoma.